HOME >> BIOLOGY >> NEWS
18F-FDG PET predicts lymphoma treatment outcome

Reston, Virginia -- A new and somewhat controversial study published in the August issue of the Journal of Nuclear Medicine suggests that 18F-FDG PET results obtained after the first cycle of treatment can better predict progression-free survival in patients with aggressive non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) than PET scans conducted at the end of treatment.

Physicians at the Weill Medical College of Cornell and the New York Presbyterian Hospital in New York reported on 23 patients who received PET scans before and after one cycle of treatment and also at the completion of chemotherapy. PET was accurate 87% of the time after one cycle but only 70% of the time after completion of chemotherapy. Sensitivity, i.e., the ability to detect the FDG and hence disease, was also significantly higher after one cycle, at 82% v. 45.5%. In particular, in cases in which results from the first cycle differed from the results following completion of therapy, the results from the first cycle scan were more accurate. Ninety percent of patients with positive 18F-FDG PET results after one cycle experienced disease relapse, while 85% who had negative 18F-FDG PET findings after one cycle remained in remission. The authors concluded that PET was a better predictor of outcome and response to therapy after just one cycle of chemotherapy than after completion.

PET stands for positron emission tomography. Because of its unique ability to measure metabolic activityor the efficiency of the cells converting food to energy--PET provides accurate, noninvasive detection and staging of many cancers. A radiopharmaceutical, such as 18F-FDG (fluorodeoxyglucose), which includes a radionuclide (a radioactive element) is injected into the patient and gives off signals that are measured by a PET scanner. Because cancer cells are more metabolically active, they show up on the PET images more intensely than normal tissue.

Using 18F-FDG PET to predict outco
'"/>

Contact: Karen Lubieniecki
karenlub@aol.com
703-683-0357
Society of Nuclear Medicine
5-Aug-2002


Page: 1 2 3

Related biology news :

1. Hardy buoys: Texas A&M project predicts oil spill movements
2. New tool predicts how long pollutants will stay in soil
3. Molecular marker predicts success of breast cancer treatment
4. Is that plant a tortoise or a hare? Answer predicts its response to environmental change
5. Brain signal predicts working memory prowess
6. New software developed at Rensselaer predicts promising ingredients for new drugs
7. Immunity gene predicts severe adverse drug reaction
8. New map predicts where wolves will attack
9. Study predicts conditions for sustainable lion trophy hunting
10. Inflammation marker predicts colon cancer
11. Doppler ultrasound predicts risk of miscarriage

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDG PET predicts lymphoma treatment outcome

(Date:10/16/2014)... 2014) – Post-menopausal women experienced improvements in vaginal ... or genital bleeding, after 12 weeks of daily ... soy germ-based nutritional supplement previously shown to help ... peer-reviewed pilot study reported in a poster at ... meeting. , "These data documented improved vaginal ...
(Date:10/15/2014)... non-traditional biophysics textbook and it describes how life functions ... discovery into biological systems and provides an understanding of ... about how our genes make proteins that control the ... in an organism. It quantifies the principles of life ... found on both large and small scales. The book ...
(Date:10/15/2014)... SHELTON, Conn. , Oct. 15, 2014 NXT-ID, Inc. ... a biometric authentication company focused on the growing mobile commerce market ... NASDAQ MarketSite in Times Square on Monday October 13 th . ... with CTO David Tunnel and angel investor Mr. ... Gino Pereira , CEO of NXT-ID thanked his investors and employees ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2New book about life as seen from physics 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
(Date:10/22/2014)... Involution Studios , a healthcare software design ... Understanding Ebola . The goal of the ... follow informative tool for anyone wanting to know more ... , "As the news has spread in all directions ... not only a healthcare crisis with global impact, but ...
(Date:10/22/2014)... 2014 Physicians Choice Laboratory Services ... menu, which enables healthcare providers to individualize therapeutic ... evidence-based results, healthcare providers are better able to ... while minimizing risks for adverse drug reactions and ... the FDA [1] more than 2.2 million adverse ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
Cached News: